Influenza A is a fragile but highly infectious RNA virus which continually re-enters the human population by one of two means. The first is by the mutation of strains that are already present in the human population. These altered strains survive by evading our adaptive immunity and cause seasonal epidemics which affect between 5% and 15% of the population every year. Most strains are not highly virulent but infections result in up to 2500 deaths in Australia each year. The majority of fatalities are in people over 65 years of age and those with significant respiratory, cardiac or renal impairment.
The second means of entry is from an animal reservoir. isolates from infected patients are resistant to amantadine, neuraminidase inhibitors are both the first-line treatment and the first choice for prophylaxis in unvaccinated people exposed to the new virus. 1 The efficacy of neuraminidase inhibitors in the treatment of severe H5N1 infections has been discouraging. This is often due to the long interval between the recognition and treatment of human infections. Early treatment appears to be beneficial. 2 The H5N1 virus can spread beyond the respiratory tree in some people. Shedding can occur at up to 10 times the rate of endemic viruses and may be prolonged for several days.
This makes the duration of acute treatment difficult to gauge, but animal studies show that it may have to be for at least 10 days. Inhaled zanamivir is untried and may only be suited to prophylaxis.
In the prophylaxis of influenza, neuraminidase inhibitors are no more than 35-75% effective. The efficacy of oral oseltamivir 75 mg daily against symptomatic influenza is 61%, or 73% for 150 mg daily. This benefit is statistically independent of the dose used. Inhaled zanamivir 10 mg daily is 62% efficacious. 3 By contrast, vaccination against endemic human influenzas is 70-90% effective depending on the antigenic 'match' with the circulating strain. 4, 5 Autumn is a time for influenza immunisation. Although the vaccine is usually given to people who are vulnerable to the complications of influenza it may be requested by healthy people. Paul Dugdale examines whether or not immunising healthy people is beneficial. Despite the stockpiling of antiviral drugs to deal with avian influenza, David Siebert says that vaccines will offer more effective prophylaxis.
